K OREAN ADNI … WHERE ARE WE NOW Seol-Heui Han, MD, PhD. On behalf of Preparatory Committee for K-ADNI Seol-Heui Han, MD, PhD. On behalf of Preparatory.

Slides:

Advertisements

Similar presentations

Department of Neurology, Mayo Clinic Arizona

Advertisements

Current Trends in Alzheimer’s Disease

December, NEED FOR VALIDATED BIOMARKERS FOR AD TRIALS Biomarkers useful in Phase 2 to make decisions about Phase 3 (e.g. doses) Biomarkers useful.

Alzheimer’s Disease Neuroimaging Initiative Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Householder, MS.

Tony WAEGEMANS, MD UCB Pharma, Belgium. TW/ll/ Washington/MCI 2 MCI as implemented in our study MCI is a very early stage of dementia with as main.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April

ADNI 3 Clinical Core Plans

CSF sulfatide is decreased in individuals with incipient dementia Xianlin Han, PhD, Anne M. Fagan, PhD, Hua Cheng, MS, John C. Morris, MD, Chengjie Xiong,

M3 Seminar December “Geriatrics” in a Nutshell Karen E. Hall, M.D., Ph.D. Clinical Assistant Professor of Internal Medicine University of Michigan.

FM&PHC HKWC Hospital Authority Family Doctor Your Health Partner Dr. Wang Hua Li, Jenny LMCHK, FKCFP, FRACGP, FHKAM (FM) Associate Consultant In-charge.

Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.

MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.

Alzheimer’s Disease and Biomarkers John H. Dougherty,Jr.M.D. Medical Director Cole Neuroscience Center.

Alzheimer’s Assessment Assessing the Cognitive-Linguistic effects of Alzheimer’s.

Dementia in Clinical Practice Mary Ann Forciea MD Clinical Prof of Medicine Division of Geriatric Medicine UPHS Photo: Nat Geographic.

Mild Cognitive Impairment

Long-term research across the population: looking to the future Fiona Matthews.

Dept. of Radiology, Xuanwu Hospital, Capital Medical University Beijing: Emeil: 首都 Update of China-ADNI Kuncheng Li.

How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.

Update Arg-ADNI Gustavo E. Sevlever, Ricardo F. Allegri (*), Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, and Arg-ADNI group. Memory and.

COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.

Disclosure of research results: should policies be changed? Melanie B. Shulman, M.D., M.Phil. Clinical Associate Professor of Neurology and Psychiatry.

Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.

HOW TO EXAMINE PATIENTS WITH DEMENTIA Serge Gauthier, MD, FRCPC McGill Centre for Studies in Aging Douglas Mental Health Research Institute.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE Michael W. Weiner.

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar ADNI Steering Committee Meeting Washington, DC April.

Assessment and Diagnosis of Dementia Dr Alison Haddow.

Geriatrics and geriatric patient Hana Vaňková, MD Assisstant Professor, 3rd Medical Faculty, Charles University in Prague Centre of Gerontology, Prague.

Update Arg-ADNI Instituto de Investigaciones Neurológicas (FLENI)

Alzheimer’s Disease: Advances and Hope Trey Sunderland, M.D. Chief, Geriatric Psychiatry Branch National Institute of Mental Health Bethesda, Maryland.

Kimiko Domoto-Reilly, MD Cognitive / Behavioral Neurology Fellow Massachusetts General Hospital & Brigham and Women’s Hospital.

Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.

Structural and Functional Neuroimaging in the Diagnosis of Dementia John M. Ringman, M.D. Assistant Professor UCLA Department of Neurology.

Sint Lucas-Andreas Hospital, Amsterdam

The status of understanding Dementia and Living Environment of Korean elderly population Eun-Ah Lee, MD., Eun Hyang Song, MD., Joon Young Lee *, MD Department.

Update of China-ADNI Kuncheng Li, MD. PhD.

ADNI3 Clinical core Paul Aisen Ron Petersen Mike Donohue

Aka STEEL VALLEY SENIORS SURVEY (SVSS)

José L Molinuevo, Craig Ritchie, Miia Kivipelto

INDIA - ADNI Dr Naren Rao

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73

Update of China-ADNI Kuncheng Li, MD. PhD.

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Presenter: Dr. Patricio Chrem

Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar

Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;

Table 2. Data Sharing for (Reporting Period)

Volume 2, Issue 1, Pages (January 2016)

Imaging AD Progression Amyloid Imaging Agents.

ADI Disease International 7-10 March, 2012

ADNI3 Clinical core Paul Aisen Ron Petersen Mike Donohue

Blood-Based Biomarkers in the QC Program?

José L Molinuevo, Craig Ritchie, Miia Kivipelto

Update of China-ADNI Kuncheng Li, MD. PhD.

ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue

National Institute of Mental Health and Neurosciences

Presenter: Dr. Patricio Chrem

Update of China-ADNI Kuncheng Li, MD. PhD.

Chris Hyde Exeter Test Group.

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Argentina Arg-ADNI Ezequiel Surace, PhD.

Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L

Dementia GEC Faculty Scholars Program

Schematic representation of core elements of geriatric assessment.

Interreg-IPA Cross-border Cooperation Programme Romania-Serbia

Detecting and Diagnosing Alzheimer’s Disease

in Younger and Older African Americans and Whites

Fig. 1. ROC curve for K-IADL to diagnose dementia or MCI

Presentation transcript:

K OREAN ADNI … WHERE ARE WE NOW Seol-Heui Han, MD, PhD. On behalf of Preparatory Committee for K-ADNI Seol-Heui Han, MD, PhD. On behalf of Preparatory Committee for K-ADNI

9yr Project 700,000 US dollars /yr Funded by the Ministry of Health, Welfare, and Family Affairs Clinical Research Center for Dementia of South Korea (CREDOS)

Primary focus of CREDOS svMCI aMCI AD SVaD Time Cognition Healthy, Healthy, SMI

Items for history Cognition ADL Behaviors Differential diagnoses Scales or questionnaires Korean Dementia Screening Questionnaire (K-DSQ) Barthel- index Instrumental ADL (Seoul IADL) NPI MMSE CDR GDS Hachinski ischemic scale Geriatric depression scale Items for history Cognition ADL Behaviors Differential diagnoses Scales or questionnaires Korean Dementia Screening Questionnaire (K-DSQ) Barthel- index Instrumental ADL (Seoul IADL) NPI MMSE CDR GDS Hachinski ischemic scale Geriatric depression scale CREDOS CREDOS protocols MRI Lab Vitamin B12 Folate VDRL TSH/free T4 Axial T2, T1, FLAIR, (GRE) Coronal T1 Neuropsychological tests

CREDOS D-Matrix WMH on MRI minimalmoderatesevere COGNITIONCOGNITION No cognitive impairmentI-1 I-2I-3 Mild cognitive impairmentII-1 II-2II-3 Mild to moderate dementiaIII-1 III-2III-3 Severe dementiaIV-1 IV-2IV-3 Healthy, SMI aMCI, AD svMCI, SIVD

DESIGNING K-ADNI

K-ADNI: Organization Tree K-ADNI PI: SH Han Clinical Core Biological Core Imaging Core Biostatistics Core Assistant administrator: SY Kim, DW Yang CREDOS PI:DL Na Advisory board ADNI: M. Weiner Stroke risk ADAS-Cog, CDR ADL,NPI, FBI Neurologic scale CSF tau, amyloid Apo E, GWAS Lipid, homocysteine, TFT MRI-VBM, DTI, fMRI FDG-PET, PIB-PET

Main aim: Effects of SVD on Progression of AD Time Cognition

Plan: 500 cases No cognitive impairment10000 Mild cognitive impairment10050 Mild to moderate dementia10050 Severe dementia000 WMH on MRI mildmoderatesevere Cognition

Recruitment N=500 Follow up K-ADNI Longitudinal 5yr Longitudinal study Neuropsychological Tests SNSB, ADL,CGA-NPI, FBI Biomarker Blood: Apo E polymorphism, Genome-wide study CSF Imaging studies MRI PET: FDG-PET, PIB-PET NPT Biomarker Imaging NPT Biomarker Imaging NPT Biomarker Imaging NPT Biomarker Imaging NPT Biomarker Imaging NPT Biomarker Imaging

Ready to go  Funding sources ($1.5 M/yr for 5 years)  Government  Private donations  Industry support